BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 19, 2025
Home » Blogs » BioWorld MedTech Perspectives

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Cerus slips as revenues weak amidst wait for FDA guidance, red blood cell expansion

May 5, 2017
By Stacy Lawrence
Cerus Corp. is optimistic that its Intercept blood system will become the standard of care in the U.S. when it comes to pathogen reduction in donor plasma and platelets. But it's been more than a couple of years since the Concord, Calif.-based company first won FDA approval in those indications. Now, it's working on a phase III clinical trial program aimed at expanding the technology's application into the broader market for pathogen reduction in red blood cells (RBCs) by the end of the decade. Cerus is also awaiting a final FDA guidance on bacterial safety...
Read More

Livanova buys Caisson in bid to lead in TMVR

May 4, 2017
By Stacy Lawrence
Livanova plc sees transcatheter mitral valve replacement (TMVR) is coming up next as a multibillion segment following on TAVR. To secure what it expects will be market-leading technology, the London-based company has acquired Maple Grove, Minn.-based Caisson Interventional LLC. Sorin SpA and Cyberonics Inc. merged in the fall of 2015 to become Livanova; Sorin had been a Caisson investor since 2012. Livanova has acquired the remaining 51 percent of Caisson for $78 million in cash, milestones and debt forgiveness. APPROACH ADVANTAGE? Caisson's TMVR implant is the only one designed entirely for use via a transseptal...
Read More

KKR, Aisling Capital enter med-tech ACT with $45M investment via Ajax Health

May 3, 2017
By Stacy Lawrence
Hedge fund giant KKR sees opportunity in a new investment approach to the medical device space. Alongside life science private equity player Aisling Capital, KKR has created Ajax Health to enable it to provide financial and operational support to medical device companies. MED-TECH OPPORTUNITY It aims to opportunistically invest in roughly seven to 10 device companies that have only one or two significant remaining risks until they reach a major inflection point. Roughly $15 million to $30 million will be invested in total for each company. The first Ajax company is Advanced Cardiac Therapeutics Inc....
Read More

Spending bill ignores president's calls for NIH, FDA cuts as HHS gets $2.8B bump

May 2, 2017
By Mari Serebrov
True to their word, U.S. lawmakers are pushing forward with plans to give the NIH its second consecutive $2 billion funding bump. Included in an omnibus spending bill Congress is slated to vote on in a few days, the increase ignores President Donald Trump's request for a $1.2 billion cut in NIH funding for the remainder of fiscal 2017 to help pay for more spending on defense. Largely due to that bump, the Department of Health and Human Services (HHS) – which includes the FDA, NIH, CDC, as well as other agencies – is slated...
Read More

Epic Sciences in $40M series D round to further develop liquid biopsy tests

May 1, 2017
By Omar Ford
Epic Sciences Inc. raised $40 million in a series D round, proving investors still have strong interest in the 9-year-old liquid biopsy specialist. The San Diego-based company has taken in about $85 million since it spun out of the Scripps Research Institute in 2008. Its most recent round was led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health Inc., Pagoda Investment, Reach Tone Ltd., RMI Partners, Sabby Capital and VI Ventures also participated in the series D financing. "As Epic has continued to grow and evolve, we see this financing round as a...
Read More

Collaboration is key to innovation in growing digital health care market

April 28, 2017
By Omar Ford
ATLANTA – The digital health market is growing. Taking in about $76.7 billion in 2015, the burgeoning space is sustained through partnerships. However, some smaller med-tech companies often have difficulties partnering with larger companies to foster innovation in the digital health market. Panelists at the Southeastern Medical Device Association (SEMDA) shared some insight on how start ups can get the attention of larger firms and forge a path in digital health. Panelist Omer Inan, an assistant professor of electrical and computer engineering at the Georgia Institute of Technology, said that traditionally the model in academia...
Read More

Device hacking, cybersecurity becoming growing concerns for med-tech companies

April 27, 2017
By Omar Ford
ATLANTA – Cybersecurity threats are becoming increasingly prevalent in the med-tech industry. Large companies are not immune to these attacks and are in some cases more of a target than smaller firms. Earlier this month Abbott Laboratories Inc. received an FDA warning letter, citing vulnerabilities with its pacemakers. (See Medical Device Daily, April 17, 2017.) The Abbott Park, Ill.-based company was brought up as an example of the growing threat of cybersecurity breaches during a panel at the Southeastern Medical Device Association's (SEMDA) annual meeting, Wednesday. Panelists presented data from BBR Services that showed 56...
Read More

Department of Defense awards Memed up to $9.2M to develop point-of-care platform

April 26, 2017
By Omar Ford
Memed Ltd. has received a contract from the Defense Threat Reduction Agency, a branch of the U.S. Department of Defense (DoD) totaling up to $9.2 million. The contract will help fund the Tirat Carmel, Israel-based company's second generation point-of-care platform for distinguishing bacterial from viral infections. Memed began operation in 2009 and has CE mark approval for the Immunoxpert, a first generation in vitro diagnostic blood test to determine whether a patient has either an acute bacterial or viral infection, said Eran Eden, the company's co-founder and CEO. "When we started this journey eight years...
Read More

BD set to make its biggest med-tech acquisition with $24B C.R. Bard buy

April 25, 2017
By Omar Ford
Becton, Dickinson and Co. (BD) is set to acquire C.R. Bard Inc. for $24 billion in cash-and-stock. The acquisition values Murray Hill, N.J.-based Bard at $317 per share, a 25 percent premium over Friday's close of trading. Bard shareholders could receive $222.93 in cash and 0.5077 shares of Franklin, Lakes N.J.-based BD for each of their shares. The acquisition is expected to close in the fall of this year. Upon news of the pending acquisition, Bard (NYSE:BCR) shares rose more than 19 percent Monday closing at $302.41. BD (NYSE:BDX) shares declined 4.4 percent closing at...
Read More

Statdx challenges major players in $2B syndromic testing market with Diagcore

April 24, 2017
By John Brosky
PARIS – Being first to market does not mean you have won the game. With competition heating up in a new category of in vitro diagnostics (IVDs) called syndromic testing, that lesson is being refreshed as a new case study takes shape. Based on multiplex polymerase chain reaction (PCR) assays, syndromic testing for infectious diseases in just a few years has captured 45 percent of the $2 billion market segment for molecular diagnostics, according to Grand View Research based in San Francisco. With a projected annual growth rate of 13.3 percent PCR-based molecular diagnostics are...
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 … 50 51 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 16, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 13, 2025
  • Illustration of liver infection

    ABI-4334 outperforms vebicorvir in HBV suppression

    BioWorld Science
    Current therapies for chronic hepatitis B virus (HBV) infection can effectively suppress viral replication but do not achieve a functional or complete cure....
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing